See how Checkpoint Therapeutics, Inc.'s FDA-approved Unloxcyt drug for cSCC is set to disrupt the market with innovative ...

Checkpoint Therapeutics Inc (CKPT) stock saw a decline, ending the day at $3.39 which represents a decrease of $-0.28 or -7.63% from the prior close of $3.67. The stock opened at $4 and touched a low ...

Checkpoint Therapeutics’ stock has seen a remarkable +60.26% year-to-date increase, far surpassing the S&P 500’s YTD performance of +26.86%. This highlights how well Checkpoint is positioning itself ...

Lake Street analyst Thomas Flaten raised the firm’s price target on Checkpoint Therapeutics (CKPT) to $7 from $4 and keeps a Buy rating on the ...

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Checkpoint Therapeutics (CKPT – Research Report), with a ...

US biotech Checkpoint Therapeutics saw its shares jump more than 16% to $4.27 in after-hours trading on Friday, on the news ...

Another checkpoint inhibitor has entered the fray, as Checkpoint Therapeutics has passed the FDA’s checkpoint with its PD-L1 inhibitor cosibelimab. The FDA has approved cosibelimab under the brand ...

Checkpoint Therapeutics (CKPT) announced that the U.S. FDA has approved unloxcyt for the treatment of adults with metastatic cutaneous squamous ...

Checkpoint Therapeutics (NASDAQ:CKPT – Free Report) had its price objective hoisted by Lake Street Capital from $4.00 to $7.00 in a research note released on Monday morning,Benzinga reports. Lake ...

Shares of Checkpoint Therapeutics rose 4.6% to $3.84 in post-market trading after the Food and Drug Administration approved Unloxcyt (cosibelimab-ipdl) for advanced cutaneous squamous cell carcinoma, ...

The U.S Food and Drug Administration said on Friday it has approved Checkpoint Therapeutics' drug for treatment of a type of ...

Unloxcyt (cosibelimab-ipdl) for metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC who are not ...